NASDAQ:SUPN - Supernus Pharmaceuticals Stock Price, Price Target & More

$48.50 -0.35 (-0.72 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$48.50
Today's Range$47.51 - $49.45
52-Week Range$29.95 - $50.04
Volume603,153 shs
Average Volume568,997 shs
Market Capitalization$2.52 billion
P/E Ratio39.40
Dividend YieldN/A
Beta1.11

About Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals logoSupernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.

Receive SUPN News and Ratings via Email

Sign-up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:SUPN
CUSIP86845910
Phone301-838-2500

Debt

Debt-to-Equity RatioN/A
Current Ratio1.86%
Quick Ratio1.72%

Price-To-Earnings

Trailing P/E Ratio39.40
Forward P/E Ratio26.22
P/E GrowthN/A

Sales & Book Value

Annual Sales$302.24 million
Price / Sales8.27
Cash Flow$1.4447 per share
Price / Cash33.57
Book Value$5.22 per share
Price / Book9.29

Profitability

EPS (Most Recent Fiscal Year)$1.26
Net Income$57.28 million
Net Margins18.95%
Return on Equity28.07%
Return on Assets18.12%

Miscellaneous

Employees422
Outstanding Shares51,540,000

How to Become a New Pot Stock Millionaire

Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals (NASDAQ:SUPN) issued its earnings results on Tuesday, February, 27th. The specialty pharmaceutical company reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.26 by $0.18. The specialty pharmaceutical company earned $88.44 million during the quarter, compared to the consensus estimate of $87.84 million. Supernus Pharmaceuticals had a net margin of 18.95% and a return on equity of 28.07%. View Supernus Pharmaceuticals' Earnings History.

When is Supernus Pharmaceuticals' next earnings date?

Supernus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Supernus Pharmaceuticals.

What price target have analysts set for SUPN?

10 brokers have issued 12 month price targets for Supernus Pharmaceuticals' stock. Their forecasts range from $41.00 to $66.00. On average, they expect Supernus Pharmaceuticals' share price to reach $51.90 in the next year. View Analyst Ratings for Supernus Pharmaceuticals.

What are Wall Street analysts saying about Supernus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (1/12/2018)
  • 2. FBR & Co analysts commented, "We are initiating coverage of Supernus Pharmaceuticals (SUPN) with a Buy rating and a 12-month price target of $53 per share. We see strong revenue growth exceeding 25% per year for 2017–2019 with in-line drugs Trokendi XR (epilepsy/ migraine) and Oxtellar XR (epilepsy) driving growth. Starting in 2020, we expect contribution from late-stage pipeline drugs SPN-812, which is a non-stimulant ADHD drug, and SPN-810 for impulsive aggression. We model EPS at $1.05 in 2017, $1.70 in 2018, and $2.35 in 2019 including a full tax rate. Our 2017 EPS estimate compares unfavorably to 2016, which included a tax benefit of $40.8 million or ~$0.80 per share. Our price target averages our DCF valuation and a P/E-derived target, which is 35x 2018E EPS of $1.70 discounted to present at 10%. At current prices, the shares have corrected by ~18% from all-time highs after an update on pipeline drug SPN-810 raised risks on timing/approvability. We see this drop as an opportunity to establish positions." (10/19/2017)
  • 3. Cantor Fitzgerald analysts commented, "Interim look at SPN-810 Phase 3 program leads to elimination of the low dose. SUPN announced that an interim analysis of the ongoing Phase 3 trials (CHIME 1 and CHIME 2) in impulsive aggression (IA) resulted in the decision to discontinue the low dose arm, 18mg daily, and randomization of future clinical trial subjects to receive either placebo or 36mg per day." (9/19/2017)

Who are some of Supernus Pharmaceuticals' key competitors?

Who are Supernus Pharmaceuticals' key executives?

Supernus Pharmaceuticals' management team includes the folowing people:
  • Mr. Jack A. Khattar, Founder, Pres, CEO, Sec. & Director (Age 57)
  • Mr. Gregory S. Patrick, VP, CFO & Principal Accounting Officer (Age 67)
  • Dr. Padmanabh P. Bhatt Ph.D., Chief Scientific Officer and Sr. VP of Intellectual Property (Age 61)
  • Mr. Victor L. Vaughn, Sr. VP of Sales and Marketing (Age 60)
  • Dr. Stefan K. F. Schwabe M.D., Ph.D., Chief Medical Officer and Exec. VP of R&D (Age 66)

Has Supernus Pharmaceuticals been receiving favorable news coverage?

Media headlines about SUPN stock have trended somewhat positive this week, according to Accern. Accern identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Supernus Pharmaceuticals earned a daily sentiment score of 0.05 on Accern's scale. They also assigned media stories about the specialty pharmaceutical company an impact score of 45.76 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Supernus Pharmaceuticals' stock price today?

One share of SUPN stock can currently be purchased for approximately $48.50.

How big of a company is Supernus Pharmaceuticals?

Supernus Pharmaceuticals has a market capitalization of $2.52 billion and generates $302.24 million in revenue each year. The specialty pharmaceutical company earns $57.28 million in net income (profit) each year or $1.26 on an earnings per share basis. Supernus Pharmaceuticals employs 422 workers across the globe.

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]


MarketBeat Community Rating for Supernus Pharmaceuticals (SUPN)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  278 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  424
MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote "Outperform" if you believe SUPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SUPN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
10 Wall Street analysts have issued ratings and price targets for Supernus Pharmaceuticals in the last 12 months. Their average twelve-month price target is $51.90, suggesting that the stock has a possible upside of 7.01%. The high price target for SUPN is $66.00 and the low price target for SUPN is $41.00. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.902.902.892.57
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $51.90$51.90$50.3333$48.2857
Price Target Upside: 7.01% upside32.91% upside8.24% upside16.63% upside

Supernus Pharmaceuticals (NASDAQ:SUPN) Consensus Price Target History

Price Target History for Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals (NASDAQ:SUPN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/1/2018Berenberg BankInitiated CoverageBuy$66.00HighView Rating Details
1/18/2018B. RileyReiterated RatingBuy -> Buy$54.00HighView Rating Details
12/4/2017Janney Montgomery ScottUpgradeNeutral -> Buy$47.00HighView Rating Details
11/7/2017Stifel NicolausUpgradeHold -> Buy$47.00N/AView Rating Details
11/3/2017SunTrust BanksReiterated RatingBuy$61.00N/AView Rating Details
10/29/2017Piper JaffraySet Price TargetHold$41.00N/AView Rating Details
10/23/2017CowenSet Price TargetBuy$50.00N/AView Rating Details
10/19/2017FBR & CoInitiated CoverageBuy -> Buy$53.00N/AView Rating Details
9/27/2017Cantor FitzgeraldReiterated RatingBuy$49.00LowView Rating Details
9/20/2017Jefferies GroupReiterated RatingBuy$51.00HighView Rating Details
7/18/2016Northland SecuritiesDowngradeOutperform -> Market Perform$24.00N/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Supernus Pharmaceuticals (NASDAQ:SUPN) Earnings History and Estimates Chart

Earnings by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals (NASDAQ:SUPN) Earnings Estimates

2018 EPS Consensus Estimate: $1.82
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184$0.26$0.35$0.29
Q2 20184$0.39$0.47$0.42
Q3 20184$0.48$0.57$0.51
Q4 20184$0.53$0.64$0.60

Supernus Pharmaceuticals (NASDAQ SUPN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018$0.30N/AView Earnings Details
2/27/2018Q4 2017$0.26$0.44$87.84 million$88.44 millionViewN/AView Earnings Details
11/6/2017Q3 2017$0.27$0.29$78.74 million$80.40 millionViewN/AView Earnings Details
8/2/2017Q2 2017$0.24$0.32$68.54 million$75.83 millionViewListenView Earnings Details
5/9/2017Q1 2017$0.22$0.19$57.91 million$57.58 millionViewListenView Earnings Details
2/28/2017Q4 2016$0.24$0.26$58.87 million$62.37 millionViewN/AView Earnings Details
1/20/2017Q3 2016$0.37$56.23 million$56.81 millionViewN/AView Earnings Details
8/2/2016Q2$0.13$0.18$49.67 million$50.40 millionViewListenView Earnings Details
5/3/2016Q1$0.09$0.08$45.33 million$43.00 millionViewListenView Earnings Details
3/2/2016Q4$0.06$0.14$42.93 million$42.70 millionViewListenView Earnings Details
11/3/2015Q315$0.02$0.08$37.93 million$38.60 millionViewListenView Earnings Details
8/5/2015Q215$0.02$0.03$34.07 million$35.10 millionViewListenView Earnings Details
5/5/2015$0.02$0.02$29.16 million$28.13 millionViewListenView Earnings Details
3/10/2015Q4 2014($0.05)$0.08$26.37 million$30.80 millionViewN/AView Earnings Details
11/11/2014Q314$0.36$0.39$43.10 million$52.50 millionViewN/AView Earnings Details
8/11/2014Q214($0.16)$0.08$19.85 million$29.67 millionViewN/AView Earnings Details
5/12/2014Q114($0.41)($0.38)$9.94 million$9.00 millionViewN/AView Earnings Details
3/12/2014Q413($0.55)($0.65)$7.78 million$10.30 millionViewN/AView Earnings Details
11/12/2013Q313($0.67)($0.78)$2.54 million$1.26 millionViewListenView Earnings Details
8/13/2013Q2 2013($0.65)($0.89)$0.91 million$0.28 millionViewN/AView Earnings Details
5/13/2013Q1 2013($0.63)($0.60)$0.57 million$0.15 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.73)($0.51)ViewN/AView Earnings Details
11/7/2012Q312($0.62)($0.55)ViewN/AView Earnings Details
8/10/2012Q2 2012($0.48)($0.61)ViewN/AView Earnings Details
6/7/2012Q1 2012($2.06)($6.05)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Supernus Pharmaceuticals (NASDAQ:SUPN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Supernus Pharmaceuticals (NASDAQ SUPN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 97.35%
Insider Trading History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals (NASDAQ SUPN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/19/2018Victor VaughnVPSell17,850$47.93$855,550.5015,594View SEC Filing  
4/5/2018Victor VaughnVPSell60,000$45.33$2,719,800.0024,344View SEC Filing  
1/22/2018Padmanabh P BhattVPSell20,000$48.04$960,800.0032,500View SEC Filing  
1/17/2018Padmanabh P BhattVPSell20,000$44.98$899,600.0032,500View SEC Filing  
1/12/2018Victor VaughnVPSell5,750$45.03$258,922.5015,094View SEC Filing  
1/11/2018Gregory S. PatrickCFOSell50,000$43.56$2,178,000.00View SEC Filing  
1/9/2018Victor VaughnVPSell15,000$42.04$630,600.0024,344View SEC Filing  
1/2/2018Victor VaughnVPSell55,000$40.11$2,206,050.00View SEC Filing  
9/8/2017Gregory S. PatrickCFOSell50,000$47.60$2,380,000.00View SEC Filing  
9/8/2017Padmanabh P BhattSVPSell5,000$49.86$249,300.0012,500View SEC Filing  
9/7/2017Stefan K.F. SchwabeInsiderSell95,000$46.59$4,426,050.00View SEC Filing  
8/16/2017Padmanabh P BhattVPSell3,709$45.23$167,758.0717,500View SEC Filing  
7/12/2017Padmanabh P BhattVPSell3,735$44.90$167,701.5021,209View SEC Filing  
6/23/2017Padmanabh P BhattVPSell2,556$44.90$114,764.4024,944View SEC Filing  
6/2/2017Padmanabh P BhattVPSell10,000$39.86$398,600.0027,500View SEC Filing  
5/26/2017Padmanabh P BhattVPSell2,500$35.90$89,750.0037,500View SEC Filing  
5/25/2017Padmanabh P BhattVPSell5,500$34.90$191,950.0043,887View SEC Filing  
4/24/2017Gregory S PatrickCFOSell54,000$32.37$1,747,980.0054,221View SEC Filing  
4/24/2017Padmanabh P BhattVPSell11,806$32.59$384,757.5445,500View SEC Filing  
9/16/2016Gregory S PatrickCFOSell2,000$25.00$50,000.003,616View SEC Filing  
7/14/2016Gregory S. PatrickCFOSell3,395$22.00$74,690.00View SEC Filing  
4/11/2016Padmanabh P BhattVPSell30,762$16.49$507,265.3857,306View SEC Filing  
12/9/2015Padmanabh P. BhattVPSell14,238$14.90$212,146.2088,068View SEC Filing  
12/8/2015M James BarrettDirectorSell212,970$14.56$3,100,843.20115,355View SEC Filing  
11/25/2015M James BarrettDirectorSell16,179$16.35$264,526.6573,929View SEC Filing  
11/18/2015M James BarrettDirectorSell93,000$16.61$1,544,730.0073,929View SEC Filing  
11/16/2015M James BarrettDirectorSell119,650$16.24$1,943,116.0073,929View SEC Filing  
11/4/2015Padmanabh P BhattVPSell5,000$19.90$99,500.00102,306View SEC Filing  
7/16/2015Gregory S PatrickCFOSell6,217$20.00$124,340.00View SEC Filing  
7/13/2015Stefan K.F. SchwabeEVPSell1,950$19.23$37,498.50View SEC Filing  
6/17/2015M James BarrettDirectorSell111,881$16.39$1,833,729.59View SEC Filing  
6/17/2015Scott D SandellMajor ShareholderSell136,597$16.50$2,253,850.50View SEC Filing  
6/16/2015M James BarrettDirectorSell55,105$16.85$928,519.25View SEC Filing  
6/16/2015Scott D SandellMajor ShareholderSell95,437$16.92$1,614,794.04View SEC Filing  
6/12/2015Stefan K.F. SchwabeEVPSell2,051$18.27$37,471.77View SEC Filing  
6/11/2015Stefan K.F. SchwabeEVPSell3,631$16.39$59,512.09View SEC Filing  
3/24/2015Jones W BryanVPSell1,900$12.00$22,800.00View SEC Filing  
8/19/2013Padmanabh BhattVPSell2,285$8.21$18,759.8551,806View SEC Filing  
3/22/2013Michael BighamDirectorBuy35,000$5.41$189,350.00View SEC Filing  
3/21/2013John M SiebertDirectorBuy3,000$5.50$16,500.00View SEC Filing  
3/15/2013Jack A KhattarCEOBuy10,000$6.15$61,500.00View SEC Filing  
3/14/2013Gregory S PatrickCFOBuy5,000$6.95$34,750.00View SEC Filing  
12/4/2012John M SiebertDirectorBuy7,000$8.14$56,980.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Supernus Pharmaceuticals (NASDAQ SUPN) News Headlines

Source:
DateHeadline
Insider Selling: Supernus Pharmaceuticals (SUPN) VP Sells 17,850 Shares of StockInsider Selling: Supernus Pharmaceuticals (SUPN) VP Sells 17,850 Shares of Stock
www.americanbankingnews.com - April 20 at 7:22 PM
Harry Boxer’s biotech-stock breakouts to watchHarry Boxer’s biotech-stock breakouts to watch
finance.yahoo.com - April 19 at 5:40 PM
Supernus Pharmaceuticals (SUPN) Upgraded to "Buy" by Zacks Investment ResearchSupernus Pharmaceuticals (SUPN) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - April 18 at 3:33 PM
Supernus Pharmaceuticals (SUPN) Downgraded by Piper Jaffray to NeutralSupernus Pharmaceuticals (SUPN) Downgraded by Piper Jaffray to Neutral
www.americanbankingnews.com - April 17 at 11:58 PM
Supernus Pharmaceuticals (SUPN) Rating Lowered to Hold at Zacks Investment ResearchSupernus Pharmaceuticals (SUPN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 17 at 6:29 PM
Supernus Pharmaceuticals (SUPN) Rating Reiterated by Stifel NicolausSupernus Pharmaceuticals (SUPN) Rating Reiterated by Stifel Nicolaus
www.americanbankingnews.com - April 17 at 5:27 PM
BidaskClub Downgrades Supernus Pharmaceuticals (SUPN) to BuyBidaskClub Downgrades Supernus Pharmaceuticals (SUPN) to Buy
www.americanbankingnews.com - April 16 at 12:19 AM
Zacks: Brokerages Expect Supernus Pharmaceuticals (SUPN) Will Post Quarterly Sales of $87.82 MillionZacks: Brokerages Expect Supernus Pharmaceuticals (SUPN) Will Post Quarterly Sales of $87.82 Million
www.americanbankingnews.com - April 15 at 2:46 AM
Supernus Pharmaceuticals (SUPN) Stock Rating Reaffirmed by CowenSupernus Pharmaceuticals (SUPN) Stock Rating Reaffirmed by Cowen
www.americanbankingnews.com - April 13 at 6:39 PM
Zacks: Brokerages Expect Supernus Pharmaceuticals (SUPN) to Announce $0.33 EPSZacks: Brokerages Expect Supernus Pharmaceuticals (SUPN) to Announce $0.33 EPS
www.americanbankingnews.com - April 13 at 5:17 PM
Form 4 SUPERNUS PHARMACEUTICALS For: Apr 05 Filed by: Vaughn VictorForm 4 SUPERNUS PHARMACEUTICALS For: Apr 05 Filed by: Vaughn Victor
www.streetinsider.com - April 11 at 5:32 PM
Factors of Influence in 2018, Key Indicators and Opportunity within Harmonic, Supernus Pharmaceuticals, America First Multifamily Investors, Ballard Power, ServiceSource International, and Materialise NV — New Research Emphasizes Economic GrowthFactors of Influence in 2018, Key Indicators and Opportunity within Harmonic, Supernus Pharmaceuticals, America First Multifamily Investors, Ballard Power, ServiceSource International, and Materialise NV — New Research Emphasizes Economic Growth
finance.yahoo.com - April 11 at 8:30 AM
Here’s What Drove Supernus Pharmaceuticals Stock in March 2018Here’s What Drove Supernus Pharmaceuticals Stock in March 2018
finance.yahoo.com - April 9 at 5:23 PM
Victor Vaughn Sells 60,000 Shares of Supernus Pharmaceuticals (SUPN) StockVictor Vaughn Sells 60,000 Shares of Supernus Pharmaceuticals (SUPN) Stock
www.americanbankingnews.com - April 9 at 1:17 PM
Commit To Purchase Supernus Pharmaceuticals At $36, Earn 14.2% Annualized Using OptionsCommit To Purchase Supernus Pharmaceuticals At $36, Earn 14.2% Annualized Using Options
www.nasdaq.com - April 6 at 5:42 PM
Piper Jaffray Analysts Give Supernus Pharmaceuticals (SUPN) a $41.00 Price TargetPiper Jaffray Analysts Give Supernus Pharmaceuticals (SUPN) a $41.00 Price Target
www.americanbankingnews.com - April 4 at 4:44 PM
Supernus Pharmaceuticals (SUPN) Given Average Rating of "Buy" by AnalystsSupernus Pharmaceuticals (SUPN) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 4 at 1:47 PM
Supernus Pharmaceuticals (SUPN) Earns "Buy" Rating from B. RileySupernus Pharmaceuticals (SUPN) Earns "Buy" Rating from B. Riley
www.americanbankingnews.com - April 1 at 10:23 AM
Edited Transcript of SUPN earnings conference call or presentation 28-Feb-18 2:00pm GMTEdited Transcript of SUPN earnings conference call or presentation 28-Feb-18 2:00pm GMT
finance.yahoo.com - March 30 at 8:22 AM
 Brokerages Anticipate Supernus Pharmaceuticals (SUPN) to Announce $0.33 EPS Brokerages Anticipate Supernus Pharmaceuticals (SUPN) to Announce $0.33 EPS
www.americanbankingnews.com - March 27 at 7:20 PM
Supernus Pharmaceuticals (SUPN) Research Coverage Started at Berenberg BankSupernus Pharmaceuticals (SUPN) Research Coverage Started at Berenberg Bank
www.americanbankingnews.com - March 25 at 9:48 PM
Supernus Pharmaceuticals Expected to Earn FY2018 Earnings of $1.84 Per Share (SUPN)Supernus Pharmaceuticals Expected to Earn FY2018 Earnings of $1.84 Per Share (SUPN)
www.americanbankingnews.com - March 23 at 9:56 AM
Supernus Pharmaceuticals (SUPN) to Post Q1 2018 Earnings of $0.35 Per Share, SunTrust Banks ForecastsSupernus Pharmaceuticals (SUPN) to Post Q1 2018 Earnings of $0.35 Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - March 22 at 8:12 AM
Supernus Pharmaceuticals (SUPN) Rating Increased to Strong-Buy at BidaskClubSupernus Pharmaceuticals (SUPN) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - March 21 at 10:36 PM
Supernus Announces Pricing of $350 Million Private Offering of ... - GlobeNewswire (press release)Supernus Announces Pricing of $350 Million Private Offering of ... - GlobeNewswire (press release)
globenewswire.com - March 16 at 8:18 AM
BRIEF-Supernus Announces Pricing Of $350 Mln Private Offering Of 0.625 Pct Convertible Senior NotesBRIEF-Supernus Announces Pricing Of $350 Mln Private Offering Of 0.625 Pct Convertible Senior Notes
www.reuters.com - March 15 at 6:13 PM
Supernus Announces Pricing of $350 Million Private Offering of 0.625% Convertible Senior Notes - NasdaqSupernus Announces Pricing of $350 Million Private Offering of 0.625% Convertible Senior Notes - Nasdaq
www.nasdaq.com - March 15 at 8:15 AM
Supernus Pharma (SUPN) Proposed Private Offering of $350 Million ... - StreetInsider.comSupernus Pharma (SUPN) Proposed Private Offering of $350 Million ... - StreetInsider.com
www.streetinsider.com - March 14 at 8:31 AM
Supernus Pharma (SUPN) Proposed Private Offering of $350 Million of Convertible Senior NotesSupernus Pharma (SUPN) Proposed Private Offering of $350 Million of Convertible Senior Notes
www.streetinsider.com - March 13 at 7:18 PM
Supernus Announces Proposed Private Offering of $350 Million of Convertible Senior NotesSupernus Announces Proposed Private Offering of $350 Million of Convertible Senior Notes
finance.yahoo.com - March 13 at 7:18 PM
Supernus Pharmaceuticals (SUPN) Rating Increased to Buy at BidaskClubSupernus Pharmaceuticals (SUPN) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 10 at 11:00 PM
Supernus Pharmaceuticals Inc (SUPN) Given Average Rating of "Buy" by BrokeragesSupernus Pharmaceuticals Inc (SUPN) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 10 at 3:11 PM
Supernus Pharmaceuticals inks deal for new, expanded headquarters - Washington Business JournalSupernus Pharmaceuticals inks deal for new, expanded headquarters - Washington Business Journal
www.bizjournals.com - March 8 at 8:22 AM
FY2018 Earnings Estimate for Supernus Pharmaceuticals Inc Issued By Cantor Fitzgerald (SUPN)FY2018 Earnings Estimate for Supernus Pharmaceuticals Inc Issued By Cantor Fitzgerald (SUPN)
www.americanbankingnews.com - March 7 at 11:50 AM
Supernus to Present at the 2018 Cowen Health Care Conference - GlobeNewswire (press release)Supernus to Present at the 2018 Cowen Health Care Conference - GlobeNewswire (press release)
globenewswire.com - March 7 at 8:16 AM
Supernus Pharmaceuticals inks deal for new, expanded headquartersSupernus Pharmaceuticals inks deal for new, expanded headquarters
finance.yahoo.com - March 6 at 5:41 PM
Supernus to Present at the 2018 Cowen Health Care ConferenceSupernus to Present at the 2018 Cowen Health Care Conference
finance.yahoo.com - March 6 at 5:41 PM
Wells Fargo & Company MN Grows Position in Supernus Pharmaceuticals Inc (SUPN)Wells Fargo & Company MN Grows Position in Supernus Pharmaceuticals Inc (SUPN)
www.americanbankingnews.com - March 6 at 3:09 PM
Supernus Pharmaceuticals Inc (SUPN) Shares Bought by Swiss National BankSupernus Pharmaceuticals Inc (SUPN) Shares Bought by Swiss National Bank
www.americanbankingnews.com - March 6 at 3:06 PM
Supernus Pharmaceuticals Inc (SUPN) Shares Bought by OppenheimerFunds Inc.Supernus Pharmaceuticals Inc (SUPN) Shares Bought by OppenheimerFunds Inc.
www.americanbankingnews.com - March 6 at 11:36 AM
Ranger Investment Management L.P. Has $21.78 Million Stake in Supernus Pharmaceuticals Inc (SUPN)Ranger Investment Management L.P. Has $21.78 Million Stake in Supernus Pharmaceuticals Inc (SUPN)
www.americanbankingnews.com - March 5 at 3:42 PM
Supernus Pharmaceuticals Inc Forecasted to Post FY2018 Earnings of $1.77 Per Share (SUPN)Supernus Pharmaceuticals Inc Forecasted to Post FY2018 Earnings of $1.77 Per Share (SUPN)
www.americanbankingnews.com - March 5 at 5:02 AM
Supernus Pharmaceuticals Inc (SUPN) Forecasted to Post Q1 2018 Earnings of $0.36 Per ShareSupernus Pharmaceuticals Inc (SUPN) Forecasted to Post Q1 2018 Earnings of $0.36 Per Share
www.americanbankingnews.com - March 5 at 1:28 AM
Q1 2018 EPS Estimates for Supernus Pharmaceuticals Inc (SUPN) Lifted by B. RileyQ1 2018 EPS Estimates for Supernus Pharmaceuticals Inc (SUPN) Lifted by B. Riley
www.americanbankingnews.com - March 5 at 1:28 AM
Supernus Pharmaceuticals Inc (SUPN) Stake Decreased by White Pine Capital LLCSupernus Pharmaceuticals Inc (SUPN) Stake Decreased by White Pine Capital LLC
www.americanbankingnews.com - March 4 at 2:46 PM
Supernus Pharmaceuticals (SUPN) Upgraded to Buy at ValuEngineSupernus Pharmaceuticals (SUPN) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - March 4 at 9:52 AM
State of Wisconsin Investment Board Raises Position in Supernus Pharmaceuticals Inc (SUPN)State of Wisconsin Investment Board Raises Position in Supernus Pharmaceuticals Inc (SUPN)
www.americanbankingnews.com - March 4 at 9:32 AM
Royce & Associates LP Sells 60,000 Shares of Supernus Pharmaceuticals Inc (SUPN)Royce & Associates LP Sells 60,000 Shares of Supernus Pharmaceuticals Inc (SUPN)
www.americanbankingnews.com - March 3 at 9:12 AM
Validea Motley Fool Strategy Daily Upgrade Report - 3/3/2018 - NasdaqValidea Motley Fool Strategy Daily Upgrade Report - 3/3/2018 - Nasdaq
www.nasdaq.com - March 3 at 8:15 AM
Arizona State Retirement System Grows Holdings in Supernus Pharmaceuticals Inc (SUPN)Arizona State Retirement System Grows Holdings in Supernus Pharmaceuticals Inc (SUPN)
www.americanbankingnews.com - March 3 at 4:22 AM

SEC Filings

Supernus Pharmaceuticals (NASDAQ:SUPN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Supernus Pharmaceuticals (NASDAQ:SUPN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Supernus Pharmaceuticals (NASDAQ SUPN) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.